
    
      This study is a multi-center, non-randomized, open label, dose-escalation, Phase 1 study of
      intravenous LY2523355 in patients with advanced and/or metastatic cancer (including
      non-Hodgkin's lymphoma) for whom no treatment of higher priority exists.
    
  